Epoch Investment Partners Inc. Decreases Stake in Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH)

Epoch Investment Partners Inc. lessened its stake in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH - Free Report) by 7.5% in the 4th quarter, according to its most recent disclosure with the SEC. The institutional investor owned 1,101,273 shares of the company's stock after selling 89,837 shares during the period. Epoch Investment Partners Inc. owned about 2.29% of Amphastar Pharmaceuticals worth $40,890,000 at the end of the most recent quarter.

Other large investors have also recently modified their holdings of the company. Pacer Advisors Inc. increased its holdings in Amphastar Pharmaceuticals by 51,977.4% during the 4th quarter. Pacer Advisors Inc. now owns 1,350,368 shares of the company's stock worth $50,139,000 after purchasing an additional 1,347,775 shares during the period. Boston Trust Walden Corp raised its holdings in shares of Amphastar Pharmaceuticals by 81.4% in the fourth quarter. Boston Trust Walden Corp now owns 978,920 shares of the company's stock valued at $36,347,000 after acquiring an additional 439,281 shares in the last quarter. Geode Capital Management LLC lifted its stake in Amphastar Pharmaceuticals by 1.5% in the third quarter. Geode Capital Management LLC now owns 920,363 shares of the company's stock worth $44,674,000 after acquiring an additional 14,015 shares during the period. Marshall Wace LLP grew its holdings in Amphastar Pharmaceuticals by 7.1% during the 4th quarter. Marshall Wace LLP now owns 608,706 shares of the company's stock worth $22,601,000 after acquiring an additional 40,212 shares in the last quarter. Finally, Renaissance Technologies LLC grew its holdings in Amphastar Pharmaceuticals by 7.4% during the 4th quarter. Renaissance Technologies LLC now owns 525,500 shares of the company's stock worth $19,512,000 after acquiring an additional 36,100 shares in the last quarter. Hedge funds and other institutional investors own 65.09% of the company's stock.

Insider Activity at Amphastar Pharmaceuticals

In other news, CFO William J. Peters sold 4,231 shares of the stock in a transaction on Tuesday, March 4th. The stock was sold at an average price of $27.54, for a total transaction of $116,521.74. Following the completion of the sale, the chief financial officer now owns 97,363 shares in the company, valued at approximately $2,681,377.02. This represents a 4.16 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 27.10% of the stock is currently owned by corporate insiders.

Analyst Upgrades and Downgrades

Several equities research analysts have recently weighed in on the stock. Piper Sandler lowered their price target on shares of Amphastar Pharmaceuticals from $36.00 to $32.00 and set a "neutral" rating for the company in a research report on Friday, March 21st. Needham & Company LLC restated a "hold" rating on shares of Amphastar Pharmaceuticals in a report on Thursday, April 10th.

Amphastar Pharmaceuticals Stock Up 0.2 %

Shares of AMPH stock traded up $0.05 during mid-day trading on Friday, hitting $24.12. 75,605 shares of the stock traded hands, compared to its average volume of 463,385. The stock's fifty day moving average is $27.17 and its two-hundred day moving average is $36.73. The company has a debt-to-equity ratio of 0.82, a current ratio of 3.43 and a quick ratio of 2.61. Amphastar Pharmaceuticals, Inc. has a 52-week low of $22.64 and a 52-week high of $53.96. The stock has a market cap of $1.15 billion, a P/E ratio of 8.05, a P/E/G ratio of 2.19 and a beta of 0.79.

Amphastar Pharmaceuticals Profile

Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. It offers BAQSIMI, a nasal spray for the treatment of severe hypoglycemia; Primatene Mist, an over-the-counter epinephrine inhalation product for the temporary relief of mild symptoms of intermittent asthma; Enoxaparin, to prevent and treat deep vein thrombosis; REXTOVY and Naloxone for opioid overdose; Glucagon for injection emergency kit; and Cortrosyn, for use as a diagnostic agent in the screening of patients with adrenocortical insufficiency.